Curcumin, a dietary pigment in curry, suppresses tumor initiation and tumor promotion. Curcumin is also a potent inhibitor for AP-1 and NF-kB activation. In this report, we show that curcumin inhibits JNK activation by various agonists including PMA plus ionomycin, anisomycin, UV-C, g radiation, TNF-a, and sodium orthovanadate. Although both JNK and ERK activation by phorbol 12-myristate 13-acetate (PMA) plus ionomycin were suppressed by curcumin, the JNK pathway was more sensitive. The IC 50 (50% inhibition concentration) of curcumin was between 5 ± 10 mM for JNK activation and was 20 mM for ERK activation. In transfection assays, curcumin moderately suppressed MEKK1-induced JNK activation; however, it eectively blocked JNK activation caused by co-transfection of TAK1, GCK, or HPK1. Curcumin did not directly inhibit JNK, SEK1, MEKK1 or HPK1 activity. Although curcumin suppressed TAK1 and GCK activities at high concentrations, this inhibition cannot fully account for the JNK inhibition by curcumin in vivo. Our data suggest that curcumin may aect the JNK pathway by interfering with the signaling molecule(s) at the same level or proximally upstream of the MAPKKK level. Taken together, the inhibition of the MEKK1-JNK pathway reveals a possible mechanism of suppression of AP-1 and NF-kB signaling by curcumin, and may explain the potent anti-in¯ammatory and anti-carcinogenic eects of this chemical.
Introduction c-Jun and c-Fos are members of the bZip transcription factor family, which contain a basic DNA-binding domain and a leucine-zipper dimerization motif. AP-1 complexes consist of a homodimer of c-Jun or a heterodimer of c-Jun/c-Fos family members (Angel and Karin, 1991; Johnson and McKnight, 1989) . These AP-1 factors can bind to the TRE (TPA-response element) sequence (Angel et al., 1987) and enhance gene expression. AP-1 factors also interact with other transcription factors including NF-kB (Stein et al., 1993) , NF-AT (Jain et al., 1993) and glucocorticoid receptor (Jonat et al., 1990; Schule et al., 1990) to regulate gene expression.
AP-1 transcriptional activity (c-Jun and c-Fos) is regulated at both transcriptional and post-translational levels . c-Jun Nterminal kinases (JNKs; also named stress-activated protein kinases, SAPKs) were recently shown to be important for the expression and post-translational modi®cation of c-Jun proteins (Derijard et al., 1994; Kyriakis et al., 1994) . JNK phosphorylates the Ser63/ Ser73 residues in the N-terminal transactivating domain of c-Jun, and strongly augments its transcriptional activity . JNK is involved in cellular responses to environmental stress, proin¯ammatory cytokines, mitogen stimulation, and apoptotic stimuli (reviewed in Kyriakis and Avruch, 1996) . The JNK subfamily, including the various isoforms of JNK1, JNK2, and JNK3, are members of the MAP kinase family (Gupta et al., 1996) . Like other MAP kinases, JNK is regulated by a kinase cascade-MEKK1 (MAPKKK)?SEK1/MKK7 (MAPKK)?JNK (MAPK) Kyriakis and Avruch, 1996; Lin et al., 1995; Sanchez et al., 1994; Tournier et al., 1997; Yao et al., 1997) . Recent work revealed that multiple MEKK1-like kinases activate the JNK pathway via SEK1/MKK4. These kinases include MEKK2-4, TAK1 (TGF-b activated kinase-1), MAPKKK5/ASK, Tpl-2/Cot, MLK3/SDPRK and MUK/DLK (reviewed in Fanger et al., 1997) . Furthermore, several yeast STE20-like kinases including p21 (Rac1/Cdc42)-activated kinases (PAKs) (Bagrodia et al., 1995; Frost et al., 1966) , germinal center kinase (GCK) (Pombo et al., 1995) , and hematopoietic progenitor kinase 1 (HPK1) (Hu et al., 1996; Wang et al., 1997) were found to be potential upstream kinases for MEKK1 or TAK1 (reviewed in Sells and Cherno, 1997) . However, others proposed that MAPKKKs (e.g. MEKKs and MLK) are parallel to, but not downstream of, PAK and GCK (Fanger et al., 1997; Gerwins et al., 1997; Teramoto et al., 1996) .
Besides c-Jun, the JNK pathway also activates the transcription factors ATF-2 (Gupta et al., 1995) , Elk-1 (Whitmarsh et al., 1995) and Sap-1a (Janknecht and Hunter, 1997) , and interacts with the NF-kB pathway . MEKK1, an upstream kinase of JNK, can induce NF-kB dependent transcription activity (Hirano et al., 1996; Lee et al., 1997; Meyer et al., 1996) . NF-kB activation may be due to the activation of the IkB-a kinase complex by MEKK1 and the subsequent degradation of the phosphorylated IkB-a (Lee et al., 1997) . Additionally, the JNK protein physically interacts with the c-Rel protein, a member of the NF-kB family, and thus, may play a role in the NF-kB signaling pathway , although the exact function of this interaction is not clear.
Curcumin (diferuloylmethane), a dietary pigment from Curcuma longa, gives the golden-yellow color and unique¯avor to curry. The anticarcinogenic eects of this compound are demonstrated by its ability to inhibit tumor initiation by azoxymethane, benzpyrene and 7,12-dimethyl-benz(a)anthracene, and to suppress tumor promotion by phorbol esters (Huang et al., 1994 (Huang et al., , 1988 Rao et al., 1995) . It has been shown that curcumin strongly inhibits both c-Jun and NF-kB activation by PMA or tumor necrosis factor-a (TNF-a) treatments (Hanazawa et al., 1993; Huang et al., 1991; Singh and Aggarwal, 1995) . This inhibitory eect may account for the anti-in¯ammatory and anti-oxidant properties of curcumin (Ruby et al., 1995; Singh and Aggarwal, 1995) ; however, the mechanism of these inhibitory eects remains unclear. In the present report, we show that curcumin completely blocked JNK activation by various agents including PMA plus ionomycin, g radiation, UV-C, anisomycin, TNF-a, and sodium orthovanadate. Curcumin inhibited both JNK and ERK activation induced by PMA plus ionomycin; however, JNK induction is more sensitive than ERK induction. By the data of in vitro and in vivo inhibition assays, we propose that curcumin may inhibit JNK induction by suppressing the regulator(s) at the same level or proximally upstream of the MAPKKK level. Curcumin has both cytostatic and cytotoxic eects, which may be associated to its inhibition of ERK and JNK activation.
Results
Curcumin blocks c-jun gene expression induced by phorbol esters (Huang et al., 1991) . JNK is capable of phosphorylating c-Jun and enhancing its transcriptional activity, which is important for c-jun gene expression. It is possible that curcumin blocks c-jun expression by suppressing JNK activation. We therefore tested whether curcumin can inhibit JNK activation induced by PMA plus ionomycin, the T-cell activation signals, in Jurkat cells. JNK activation induced by PMA plus ionomycin was completely blocked by pretreatment of Jurkat T cells with curcumin (50 mM) for 1 h (Figure 1 ). To examine whether curcumin could inhibit the eects of other JNK stimuli, several other agonists were tested. We found the pretreatment of curcumin suppressed JNK activation induced by all of the tested agents including UV-C, g radiation, anisomycin and TNF-a ( Figure 1 ). This inhibition of JNK activation could be due to either the suppression of the upstream activator(s) of JNK or the enhancement of the activity of dual-speci®city JNK phosphatases, which are known to suppress JNK activity (Chu et al., 1996; Muda et al., 1996) . However, curcumin also inhibited JNK activation induced by the phosphatase inhibitor, sodium orthovanadate (Figure 1 ), which inhibits the dual-speci®city JNK phosphatases. Therefore, the results suggest that curcumin most likely blocked JNK activation by inhibiting the upstream activator(s) of the JNK pathway.
To examine whether curcumin inhibits the JNK pathway speci®cally, we studied the dose response of curcumin's inhibitory eects on both JNK and ERK activation induced by PMA plus ionomycin in Jurkat cells. Curcumin blocked JNK activation in a dosedependent manner and a complete inhibition of JNK activation was observed in treatments with around 40 mM of curcumin (Figure 2a and b). The IC 50 (50% inhibitory concentration) for JNK inhibition was between 5 ± 10 mM ( Figure 2b ). Similar inhibition curves were observed in anisomycin and UV-C- Figure 1 Curcumin inhibits JNK activation by various agonists. Jurkat T cells were incubated in medium with or without curcumin (50 mM) for 1 h, and then treated with various JNK agonists including PMA (50 ng/ml) plus ionomycin (1 mM), g radiation (80 Gy), UV-C (200 J/m 2 ), anisomycin (2 mg/ml), and sodium orthovanadate (1.5 mM). MCF-7 cells were cultured with or without curcumin (50 mM) for 1 h, and then treated with TNF-a (100 ng/ml). Cells were collected at dierent time points as indicated, and the endogenous JNK1 activity was determined by immunocomplex kinase assays a b Figure 2 Curcumin inhibits both JNK and ERK activation. (a) Jurkat T cells were incubated in medium containing dierent concentrations of curcumin for 1 h, and then were stimulated with PMA (50 ng/ml) plus ionomycin (1 mM) for 30 min. Endogenous JNK1 and ERK2 activities were determined by immunocomplex kinase assays using GST-Jun(1 ± 79) and MBP, respectively, as substrates. (b) The kinase activation shown in panel a was quantitated with a densitometer. Residual kinase activity after curcumin treatment was presented as a percentage of maximum induction, which is kinase activation by PMA plus ionomycin in the absence of curcumin. For quantitation of MBP phosphorylation, both phosphorylated protein bands were measured and the average value were presented. Data presented are the means and standard deviations of three measurements induced JNK activation (data not shown). ERK2 induction by PMA plus ionomycin was also sensitive to curcumin treatment ( Figure 2a and b) ; however, the IC 50 was 20 mM, which was higher than that for JNK inhibition (Figure 2b) . Furthermore, although curcumin suppressed ERK2 induction by PMA plus ionomycin, incubation with curcumin did not abolish the ERK2 basal activity even at a concentration of 80 mM (Figure 2a) .
JNK and ERK activities are required for mitogenic signaling and cell proliferation (reviewed in Robinson and Cobb, 1997; Whitmarsh and Davis, 1996) . Therefore, inhibition of these pathways by curcumin should aect cell growth and survival. Jurkat T cells were incubated in media containing 0, 10, 20 or 40 mM of curcumin, and were examined for the next 3 days. The cells cultured with normal medium had a doubling time of around 36 h. Incubation of the cells in 10 mM curcumin slowed the growth rate in comparison with the control (Figure 3a) ; however, it did not change the survival rate signi®cantly (Figure 3b ). Higher concentrations (20 and 40 mM) of curcumin completely suppressed the cell growth and induced signi®cant cell death after day 2 (Figure 3a and b) . These results indicate that the ability of curcumin to suppress cell proliferation was correlated with its ability to suppress JNK and ERK activities ( Figure 2b ) and that curcumin has both cytostatic and cytotoxic eects depending on drug concentrations and the duration of treatment.
Because of the eective inhibition of JNK activation by curcumin, we further examined the molecular target of curcumin. In vitro incubation of curcumin with puri®ed JNK recombinant proteins did not inhibit their ability to phosphorylate GST-Jun proteins (Figure 4a) . Incubation of curcumin with GST-SEK1 proteins also failed to suppress SEK1 activity, as assayed by using GST-SAPK(KR), a kinase-dead mutant, as a substrate (Figure 4a) . Similarly, curcumin did not abolish in vitro phosphorylation of GST-SEK1 by puri®ed GST-MEKK1 (Figure 4a ). These data indicate that curcumin does not directly inhibit the kinase function of JNK, SEK1, and MEKK1. We then transfected the HA-tagged JNK plasmid with plasmids encoding various upstream kinases including SEK1 (Sanchez et al., 1994) , MEKK1 (Yan et al., 1994) , TAK1 (Yamaguchi et al., 1995) , GCK (Pombo et al., 1995) , and HPK1 (Hu et al., 1996) into 293 cells. The transfected cells were cultured in complete medium for 6 h for recovery, and then were treated with or without 20 mM of curcumin for 24 h. The JNK activity was determined by immunoprecipitating the kinase with an anti-HA antibody, followed by kinase assays. Curcumin treatment did not inhibit JNK activity isolated from cells transfected with HA-JNK alone or in combination with SEK1, in contrast, it enhanced the JNK activation by SEK1 in vivo in repeated experiments (Figure 4b and data not shown). JNK activity induced by MEKK1 was only slightly inhibited by curcumin (Figure 4b ). These results are consistent with the in vitro inhibition experiments that JNK, SEK1 and MEKK1 may not be direct targets for curcumin's inhibitory eect. In contrast, curcumin signi®cantly suppressed JNK induction by co-expression of TAK1, GCK, and HPK1 (Figure 4b ). Curcumin did not signi®cantly aect the expression of HA-JNK (Figure 4b ), indicating that this in vivo inhibition was not due to the suppression of HA-JNK expression.
Because curcumin suppressed the JNK activation by TAK1, HPK1 and GCK in vivo, we further examined whether these JNK upstream kinases are the direct targets of curcumin. We immunoprecipitated the individual kinases from 293 cells transfected with HPK1, TAK1, or GCK and performed in vitro kinase assays using myelin basic protein (MBP) as a substrate in the presence of various concentrations of curcumin. The kinase activity of HPK1 was not aected by coincubation with curcumin ( Figure 5 ). Curcumin inhibited MBP phosphorylation by TAK1 and GCK at high concentrations; however, as observed in repeated experiments, it did not abolish the kinase activities even at the highest concentration tested (Figure 5 and data not shown) . Because curcumin inhibited JNK activation eectively at lower concentrations in experiments in vivo (Figures 1 and 2) , this moderate inhibition of TAK1 and GCK does not fully account for the curcumin's inhibitory eect on the JNK pathway in vivo.
Discussion
Curcumin is a dietary compound with the known properties of antioxidation, anti-in¯ammation, and anticarcinogenesis (Huang et al., 1994; 1988; Rao et al., 1995; Ruby et al., 1995; Singh and Aggarwal, 1995) . Curcumin blocks c-jun expression and NF-kB activation induced by various agents (Hanazawa et al., 1993; Huang et al., 1991; Singh and Aggarwal, 1995) . This inhibitory eect is believed to be the major mechanism for the biological eect of this chemical. However, the mechanism by which curcumin inhibits transcriptional activation remains unknown. In this report, we showed that curcumin completely blocked JNK activation by various agonists. Curcumin was more eective in blocking JNK activation than ERK activation induced by PMA plus ionomycin, and it failed to eliminate basal ERK activity (Figure 2 ). This may explain the observation in a previous report that curcumin preferentially inhibits c-jun gene expression, but not c-fos expression, induced by PMA stimulation (Huang et al., 1991) . c-Jun transcriptional activity, which is dependent on JNK activation, is essential for its own gene expression (Karin, 1995) . Thus inhibition of JNK by curcumin would result in the inhibition of c-Jun activation and transcription of the c-jun gene. In contrast, c-fos gene expression is more dependent on ternary complex factors, which can be activated by the ERK pathway and bind to the serum-response element (Karin, 1995) . Therefore, c-fos expression induced by PMA is less aected by curcumin.
By the in vitro inhibition assays, we showed that kinase activities of JNK, SEK1, MEKK1, and HPK1 may not be the direct targets of curcumin's inhibitory eect. However, curcumin moderately inhibit MEKK1-induced JNK activation and eectively inhibited JNK activation by coexpression of TAK1, HPK1, and GCK. Although curcumin suppressed TAK1 and GCK activities at high concentrations in vitro, these inhibitory eects probably cannot fully account for the inhibition of JNK activation in vivo. The fact that curcumin inhibited JNK induction by various agonists (Figure 1) implies that curcumin interferes with the proximal upstream rather than the distal upstream of the JNK pathway. Our results suggest that curcumin may act on regulators at the same level or proximally upstream of the MAPKKK level. The inhibition of upstream regulators can lead to the unresponsiveness of the JNK cascade (MEKK1-SEK-JNK). MEKK1 has been shown to enhance the NF-kB transcription activity (Hirano et al., 1996; Meyer et al., 1996) , and is a candidate for the kinase that activates the IkB kinase complex (Lee et al., 1997) . The IkB kinase complex phosphorylates IkB and this results in its degradation and the activation of NF-kB (Chen et al., 1996c) . Our data suggest that inhibition of the MEKK1-JNK pathway by curcumin may also contribute to the suppression of NF-kB activation. Therefore, through Figure 5 Eect of curcumin on TAK1, HPK1 and GCK kinase activities in vitro. TAK1, HPK1, or GCK was immunoprecipitated from cell lysates prepared from 293 cells transfected with the individual wild-type or dominant-negative kinases. The precipitated kinases were incubated with dierent concentration of curcumin in kinase buer for 10 min at room temperature, then myelin basic proteins (MBP) were added as substrates in the presence of [g-32 P]ATP for kinase reactions (30 min at 308C). Phosphorylation of the substrate was analysed by SDS ± PAGE and autoradiography inhibition of the JNK signaling module, curcumin can eectively block both AP-1 (c-Jun) and NF-kB signaling pathways.
AP-1 and NF-kB activities are important for cell proliferation and both activities are required for expression of immediate-early or early genes, such as IL-2 and IL-2 receptor in lymphocytes (Kelly and Siebenlist, 1995) . In this report, we show that curcumin inhibited both the JNK and ERK pathways. The inhibition of the ERK and JNK pathways and the suppression of AP-1 and NF-kB can block cell growth. Thus, the anticarcinogenic eect of curcumin may be due to its inhibition of these cellular pathways and suppression of cell growth. Besides cell proliferation, AP-1 and NF-kB are also involved in the cellular reaction to in¯ammatory cytokines such as interleukin-1 and TNF-a (Brenner et al., 1989; Finco and Baldwin, 1995; Muegge et al., 1989) , which play important roles in many immune responses. Curcumin's ability to block AP-1 and NF-kB could be a useful tool in controlling in¯ammatory and autoimmune diseases.
Materials and methods

Cells, antibodies and reagents
Human Jurkat T cells (clone J.LEI) were cultured in RPMI-1640 supplemented with 10% fetal calf serum and streptomycin/penicillin. MCF-7 cells and human embryonic kidney 293 cells were cultured in DMEM supplemented with 10% fetal calf serum and streptomycin/penicillin. Rabbit anti-JNK1 (Ab101) and anti-HPK1 (Ab2025) antibodies were described previously (Chen et al., 1996a; Hu et al., 1996) . Anti-ERK2 (#C-14), anti-TAK1 (#M-17), and anti-GCK (#N-19) antibodies were purchased from Santa Cruz. The anti-HA antibody (#12CA5) was purchased from Boehringer Mannheim. Curcumin, PMA, ionomycin, and anisomycin were purchased from Sigma. Recombinant JNK protein was purchased from Stratagene. Recombinant human TNF-a was purchased from R&D System.
Plasmids
GST-Jun(1-79), pCIneo-HPK1, pCIneo-HPK1-M(46), and HA-JNK plasmids were described previously (Hu et al., 1996; Wang et al., 1996) . The GST-SAPK(KR) and pUna3-MEKK1 were kindly provided by D Templeton (Case Western Reserved U, Cleveland, OH), the GCK plasmid was a gift from J Kehrl (NIH, Bethesda, MD), pEBG-SEK1 was a gift from L Zon (Harvard Medical School, Boston, MA), and the TAK1 and TAK1(K63W) plasmids were gifts from K Matsumoto (Nagoya University, Nagoya, Japan).
Cell transfection and treatment
Brie¯y, 293 cells were plated 24 h before transfection at a density of 1.5610 5 per 35 mm well. Cells were cotransfected with the HA-JNK plasmid in combination with dierent expression plasmids for the upstream kinases as indicated. The transfections were performed by a calcium phosphate precipitation protocol (Specialty Media) with duplicates in each transfection. After removing the transfection mixture, the cells were incubated in complete medium for 6 h for recovery, then treated with or without curcumin for 24 h.
Cell extracts preparation and immunocomplex kinase assays
Whole cell lysate was prepared by suspending 2610 6 cells in 200 ml lysis buer (20 mM HEPES [pH 7.4], 2 mM EGTA, 50 mM glycerophosphate, 1% Triton X-100, 10% glycerol, 1 mM dithiothrietol [DTT] , 2 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride [PMSF], 1 mM sodium orthovanadate). The cell lysates were kept on ice and vigorously vortexed every 5 min for 20 min. The lysates were cleared by centrifugation at 15 000 g for 3 min, and the supernatants were stored at 7808C. Kinase assays were carried out as described (Chen et al., 1996b) . Kinases were precipitated by incubation with indicated speci®c antibodies and protein A-agarose beads (Bio-Rad) in the lysis buer at 48C for 3 h. The precipitates were washed twice with the lysis buer, twice with the LiCl buer (500 mM LiCl, 100 mM Tris-Cl [pH 7.6] and 0.1% Triton X-100), and twice with the kinase buer (20 mM 4-morpholinepropane-sulfonic acid [MOPS; pH 7.6], 2 mM EGTA, 10 mM MgCl 2 , 1 mM DTT, 0.1% Triton X-100 and 1 mM sodium orthovanadate), then mixed with 5 mg of substrate (GST-Jun(1 ± 79) or MBP), 15 mM of ATP, and 10 mCi of [g-32 P]ATP in 30 ml of kinase buer. The kinase reaction was performed at 308C for 30 min, then terminated by adding SDS sample buer. The reaction mixtures were boiled and analysed by SDS ± PAGE and autoradiography.
Abbreviations JNK, c-Jun N-terminal kinase; ERK, extracellular signalregulated kinase; MAPK, mitogen-activated protein kinase; MAPKK, MAPK kinase; MAPKKK, MAPK kinase kinase; SEK, SAPK and ERK kinase; MEKK1, MAPK kinase kinase-1; TGF-b, transforming growth factor-b; TAK1, TGF-b activated kinase-1; GCK, germinal center kinase; HPK1, hematopoietic progenitor kinase-1; PMA, phorbol 12-myristate 13-acetate; TNF-a, tumor necrosis factor-a; MBP, myelin basic protein.
